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Obesity is characterized by excess body fat accumulation due to an increase in the size and number of differentiated mature
adipocytes. Adipocyte differentiation is regulated by genetic and environmental factors, and its inhibition could represent a
strategy for obesity prevention and treatment. The current study was designed with two aims: (i) to evaluate the changes
in the expression of adipogenic markers (C/EBPα, PPARγ variant 1 and variant 2, and GLUT4) in 3T3-L1 murine
preadipocytes at four stages of the differentiation process and (ii) to compare the effectiveness of sulforaphane, genistein,
and docosahexaenoic acid in reducing lipid accumulation and modulating C/EBPα, PPARγ1, PPARγ2, and GLUT4 mRNA
expression in mature adipocytes. All bioactive compounds were shown to suppress adipocyte differentiation, although with
different effectiveness. These results set the stage for further studies considering natural food constituents as important
agents in preventing or treating obesity.
1. Introduction
Obesity is the main dysfunction of adipose tissue and is
associated with premature death and the development of
chronic diseases such as cardiovascular diseases (CVD), type
2 diabetes, hypertension, and certain cancers [1]. In particu-
lar, a chronic inflammation in the absence of overt infection
or autoimmune process is a puzzling phenomenon linked to
obesity [2].
Environment, lifestyle, and genetic susceptibility cer-
tainly contribute to the increased risk of obesity, one of the
easiest to be recognized and the most difficult to treat medical
conditions [3]. Antiobesity drugs lack physiology specificity
and have side effects [4].
Obesity is characterized by an excess accumulation of
white adipose mass, resulting from both the increase in
adipocyte cell size and the development of mature cells
from undifferentiated precursors. Particularly, de novo
generation of fat cells plays a key role in the development
of obesity.
Discovering compounds able to regulate the size, num-
ber, and function of adipocytes and understanding their
mechanisms of action could greatly contribute to obesity
prevention and treatment. In this light, natural compounds
represent a potential novel strategy, already exploited for pre-
venting other metabolic disorders [5]. Bioactive compounds
have been shown to exert specific effects on the biochemical
and metabolic functions of adipocytes [6–8], in particular
inhibition of preadipocyte differentiation, lipolysis stimula-
tion, and induction of apoptosis of existing adipocytes [9],
therefore contributing to a possible decrease in adipose tissue
mass [10].
The aim of the current study was to compare the antiadi-
pogenic effect of three bioactive compounds, namely, docosa-
hexaenoic acid (DHA), genistein (GEN), and sulforaphane
(SFN). DHA (C22:6 n-3) is an n-3 polyunsaturated fatty acid
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(PUFA) abundant in fatty fish. It is considered effective in the
prevention of many chronic diseases, mainly CVD [11]. GEN
(4,5,7-trihydroxyisoflavone), the most abundant isoflavone
found in soybeans, has received particular attention for its
structural similarity to estrogen and its high affinity to the
estrogen receptor. It is a well-known antioxidant, chemopre-
ventive, and anti-inflammatory agent [12, 13]. SFN, an
isothiocyanate compound, is a constituent of cruciferous
vegetables such as broccoli sprouts, Brussels sprouts, and
cabbage. SFN is known to have antioxidant, immunomodu-
latory, anticancer, and antidiabetic properties [14, 15].
In some previous earlier studies [16–19], all tested bioac-
tive compounds have been shown to be antiadipogenic in the
3T3-L1 cell line. Notwithstanding, to our knowledge, their
effectiveness has never been compared in the same experi-
mental conditions. Although in vitro studies always need
confirmation in vivo, the selection of the most active bioac-
tive could be useful to formulate functional foods contribut-
ing to the development of new strategies to prevent obesity.
3T3-L1 cells constitute the most frequently used preadi-
pocyte model, sharing many properties with normal adipo-
cytes [20]. Their differentiation into mature adipocytes
involves the exposure of a confluent, quiescent population
of cells to a variety of effectors that activate a complex
cascade of genes [21].
It is well documented that adipogenesis is finely con-
trolled by key transcription factors such as peroxisome
proliferator-activated receptor-γ (PPARγ) and CCAAT-
enhancer-binding protein-α (C/EBPα). PPARγ and C/
EBPα regulate the expression of various genes involved
in lipogenesis, lipolysis, and insulin sensitivity, such as
the one encoding for glucose transporter type 4 (GLUT4)
[22, 23]. In the first part of the study, changes in the
expression of PPARγ, C/EBPα, and GLUT4 genes were
evaluated in the murine 3T3-L1 cell line at various stages
of the differentiation process.
In the second part of the study, preadipocytes were
supplemented during and after differentiation with DHA,
GEN, and SFN, and both lipid accumulation and the mRNA
expression of PPARγ, C/EBPα, and GLUT4 were evaluated
to evidence and compare their potential inhibitory activity
on adipogenesis.
2. Materials and Methods
Dulbecco’s modified Eagle’s medium (DMEM)/F12
GlutaMAX I was purchased from Invitrogen (Darmstadt,
Germany), donor bovine serum (DBS) was from Gibco Life
Technologies (Darmstadt, Germany), fetal bovine serum
(FBS GOLD) was from PAA Laboratories (Pasching,
Austria), and TRIzol Reagent was from Ambion, Life Tech-
nologies (Darmstadt, Germany). All other chemicals were
purchased from Sigma-Aldrich (Schnelldorf, Germany) and
were of the highest analytical grade.
2.1. Cell Culture and Differentiation. 3T3-L1 mouse preadi-
pocytes were obtained from the American Type Culture
Collection (ATCC) and maintained at 37°C in a humidified
atmosphere containing 95% air and 5% CO2; preadipocytes
were subcultured every three days when 80% confluent or
less into a new 175 cm2 flask. Cells were cultured in
DMEM/F12 GlutaMAX I with the addition of D-glucose
(3151mg/L f.c.) (GM) containing 10% DBS and 1% peni-
cillin/streptomycin (PS). Cells were seeded in 12-well
plates or a 25 cm2 flask at a concentration of 50,000
cells/mL. Three days after seeding, cells were stimulated to
differentiate with GM supplemented with 10% FBS, 1% PS,
insulin (10μg/mL), dexamethasone (1μM), isobutylmethyl-
xanthine (0.2mM), and rosiglitazone (10μM) (differentia-
tion medium). After further 3 days (differentiation), cells
were maintained in GMwith FBS, PS, and insulin (postdiffer-
entiation medium) for another 5 days (postdifferentiation)
when approximately 90% of the cells displayed the character-
istic lipid-filled adipocyte phenotype.
2.2. Bioactive Supplementation. DHA, GEN, and SFN were
added to the differentiation and postdifferentiation medium
at three different final concentrations (10, 25, or 50μM).
The SRB assay was performed in preliminary experiments,
evidencing no cytotoxicity for any of the tested concentra-
tions of each bioactive.
The treatment with bioactives began three days after
seeding and lasted until the end of postdifferentiation (eleven
days from seeding). All bioactive compounds were purchased
from Sigma-Aldrich (Schnelldorf, Germany). Each com-
pound was dissolved in dimethyl sulfoxide (DMSO). Unsup-
plemented control cells (CTR) received a corresponding
amount of DMSO (<0.5% final concentration). The medium
was changed every two days during postdifferentiation.
2.3. Lipid Staining. The effect of the bioactive compounds
on adipogenesis was evaluated morphologically by staining
accumulated lipids with Oil Red O [24] as previously
described [25]. Briefly, cells were fixed with 4% formalin
solution in phosphate-buffered saline (PBS) for two hours,
washed with water, rinsed with isopropanol 60%, and
stained with Oil Red O for 30 minutes at room tempera-
ture. After washing with distilled water for 3 times, the
lipid droplets were quantified by dissolving Oil Red O in
isopropanol 100% and measuring the optical density at
500 nm.
The lowest bioactive concentrations able to influence
lipid accumulation (10μM GEN, 10μM SFN, 25μM DHA)
were then used in gene expression experiments.
2.4. Gene Expression Analysis. Unsupplemented, control
cells were collected at four different steps of the differenti-
ation protocol: one day after seeding (T1); three days after
seeding (postconfluent cells), before the beginning of
differentiation (T2); six days after seeding (end of the
differentiation), before the addition of the postdifferentia-
tion medium (T3); and eleven days after seeding, at the
end of postdifferentiation (T4). Cells were collected at
the different time points, and total RNA was extracted as
described below.
In experiments evaluating bioactives’ effect, 10μM GEN,
10μM SFN, or 25μM DHA was added to the differentiation
and postdifferentiation media as described above. At the end
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of the postdifferentiation period (T4), cells were collected,
and total RNA was extracted with TRIzol Reagent following
the manufacturer’s protocol. Contaminating DNA was elim-
inated by DNase treatment (DNA-free Kit from Ambion,
Life Technologies, Darmstadt, Germany). RNA quantity
and quality, respectively, were assessed by spectrophotomet-
ric analyses at 260/230 nm using a NanoDrop ND-2000
spectrophotometer (Thermo Fisher Scientific, Wilmington,
DE, USA) and by the microfluidics-based Bioanalyzer plat-
form with an RNA Nano 6000 Chip (Agilent Technology,
Waldbronn, Germany).
cDNA was synthesized from 0.5μg or 1μg of DNase-
treated total RNA using SuperScript II reverse transcriptase
(Invitrogen, Darmstadt, Germany) according to the manu-
facturer’s instructions. Quantitative real-time PCR (qPCR)
was performed using the Universal ProbeLibrary system
(Roche, Mannheim, Germany) on a Roche LightCycler
480 real-time PCR system (Roche, Mannheim, Germany).
The cycling program for analysis was 15min at 95°C
followed by 45 cycles of 10 s at 95°C, 20 s at 55°C, and
10 s at 72°C with the primer pairs and the respective monoco-
lor hydrolysis probes indicated in Table 1. The expression
levels of target mRNAs were normalized to three reference
genes: β-actin (ACTB), hypoxanthine phosphoribosyltrans-
ferase 1 (HPRT1), and TATA-box-binding protein (TBP).
2.5. Statistical Analysis. Gene expression data were analyzed
using DataAssist software version 3.01 (Applied Biosystems,
Foster City, CA, USA) and expressed as the mean fold change
in relative expression compared with the untreated control
cells, which were normalized to one. Average fold change
and standard deviation (SD) were obtained from three
biological replicate samples per condition.
All data were analyzed by one-way ANOVA, followed by
Dunnett’s or Tukey’s tests. Statistical analysis of the data was
performed using the GraphPad Prism 5 software (San Diego,
CA, USA).
3. Results
3.1. Characterization of Preadipocyte Differentiation. Dur-
ing differentiation (T1–T4), preadipocytes acquired the
characteristics of mature adipocytes. At three days after
seeding (T2), nondifferentiated cells showed typical fibro-
blastoid morphology, while at the end of the differentia-
tion process (T4), cells had abundant intracytoplasmic
lipid accumulation, showing typical white adipocyte mor-
phology (Figure 1).
To characterize the differentiation process, PPARγ1,
PPARγ2, C/EBPα, and GLUT4 gene expression was evalu-
ated at four different stages of adipocyte differentiation:
one day after seeding (T1), three days after seeding (T2),
at the end of the differentiation (T3), and at the end of
postdifferentiation (T4).
The expression of selected genes was very low and similar
at T1 and T2, while it significantly increased at T3. For all
analyzed genes, a prominent increase in mRNA levels was
observed in mature adipocytes (T4) (Figure 2).
3.2. Effects of Bioactive Compound Supplementation. The
antiadipogenic potential of DHA, GEN, and SFN was first
investigated evaluating their influence on lipid accumula-
tion. Preadipocytes were supplemented with different con-
centrations (10, 25, and 50μM) of the test compounds
during the differentiation and postdifferentiation periods,
as described above, and lipid accumulation was detected
by Oil Red O staining. All bioactive compounds markedly
reduced lipid droplet formation compared to controls.
GEN and SFN were effective at the lowest concentration
used for supplementation (10μM), while a higher DHA
concentration (25μM) was required to reduce lipid accu-
mulation (Figure 3).
The lowest bioactive concentrations causing a significant
decrease in lipid accumulation were used to verify the modi-
fication in the mRNA levels of the adipogenesis marker genes
after differentiation.
At T4, all bioactive compounds significantly reduced
the transcript levels of PPARγ1, PPARγ2, C/EBPα, and
GLUT4. The effect of GEN and SFN on PPARγ and
GLUT4 expression appeared stronger than the DHA effect
did (Figure 4).
4. Discussion
Adipose tissue has an important function in the energy bal-
ance by regulating lipid metabolism, glucose homeostasis,
Table 1: Primer sequences used in qPCR.
Gene Forward primer Reverse primer Probe number
Target genes
PPARγ1 GAAAGACAACGGACAAATCACC GGGGGTGATATGTTTGAACTTG 7
PPARγ2 TGCTGTTATGGGTGAAACTCTG CTGTGTCAACCATGGTAATTTCTT 2
C/EBPα AAACAACGCAACGTGGAGA GCGGTCATTGTCACTGGTC 67
GLUT4 GACGGACACTCCATCTGTTG GCCACGATGGAGACATAGC 5
Reference genes
ACTB GTGGGAGAGCAAGGAAGAGA CACTCTTGGCCCAGTCTACG 56
HPRT1 TCCTCCTCAGACCGCTTTT CCTGGTTCATCATCGCTAATC 95
TBP CGGTCGCGTCATTTTCTC GGGTTATCTTCACACACCATGA 107
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and adipokine secretion. Thus, its dysfunction is critical in
developing metabolic diseases [26]. Indeed, the incidence of
metabolic syndrome, a combination of cardiometabolic risk
determinants, is increasing worldwide largely as a conse-
quence of the continued obesity epidemic [27].
In general, obesity is related to the extent of adipocyte
differentiation, intracellular lipid accumulation, and lipoly-
sis [17]. The process of adipocyte differentiation requires
the activation of numerous transcription factors which
are in charge of the coordinated induction and silencing
of more than 2000 genes [28]. Several transcriptional reg-
ulators, including C/EBP and PPARγ, play a pivotal role
in this process.
The master regulator PPARγ is both necessary and suffi-
cient for adipogenesis [29, 30]. PPARγ has two isoforms, the
ubiquitary PPARγ1 and the adipose tissue-specific PPARγ2.























































Figure 2: (a) PPARγ1, (b) PPARγ2, (c) C/EBPα, and (d) GLUT4 mRNA expression at 4 different stages of adipocyte differentiation. T1: one
day after seeding; T2: three days after seeding, before the beginning of differentiation; T3: at the end of the differentiation, before the addition
of the postdifferentiation medium; T4: at the end of postdifferentiation (mature adipocytes). Data are expressed as the mean fold change
relative to the mature cells (T4), normalized to one. Statistical analysis was by one-way ANOVA (p < 0 001 for all panels) followed by
Tukey’s HSD test. The expression is significantly different between groups marked with different letters (at least p < 0 05).
(a) (b) (c)
Figure 1: Morphological changes among (a) preadipocytes three days after seeding (T2), (b) adipocytes at the end of the differentiation (T3),
and (c) adipocytes at the end of postdifferentiation (T4). Images showing different cell morphologies were captured at the different steps using
a Leica DM IL microscope (Wetzlar, Germany), with 10x magnification.
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Both isoforms are strongly induced during preadipocyte dif-
ferentiation [25], and our data confirm that PPARγ1 induc-
tion foreruns PPARγ2 induction [31].
C/EBPβ and C/EBPδ are overexpressed in the earlier
phases of differentiation and have been shown to play a role
in PPARγ induction [30]. C/EBPα is involved in the
maintenance of the terminally differentiated adipocyte phe-
notypes [28, 32, 33]. In agreement, we observed a lower C/
EBPα expression at T1 and T2 than at T3 and T4.
In adipocytes, C/EBPα regulates the expression of the
gene encoding for GLUT4, the major insulin-responsive glu-



























































































Figure 3: Lipid accumulation in supplemented and control cells. Data are expressed as a percentage relative to unsupplemented control cells
(CTR), assigned as 100%. Statistical analysis was performed by one-way ANOVA (p < 0 001) followed by Dunnett’s test: ∗∗∗p < 0 001 versus
CTR. ND: nondifferentiated cells, before the beginning of the differentiation process.























































Figure 4: Modulatory effect of GEN, SFN, and DHA on (a) PPARγ1, (b) PPARγ2, (c) C/EBPα, and (d) GLUT4 mRNA expression. Data are
expressed as the mean fold change relative to the unsupplemented control cells (CTR) at T4, normalized to one. Statistical analysis was by
one-way ANOVA (p < 0 001 for all panels) followed by Tukey’s HSD test. The expression is significantly different between groups marked
with different letters (at least p < 0 05).
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cardiac muscles [34]. Accordingly, in the present study,
GLUT4 expression paralleled C/EBPα expression.
Overall, our results confirm that differentiation of 3T3-
L1 cells includes distinguishable multiple stages [35, 36].
Our results evidence that all tested bioactives efficiently
block adipocyte differentiation. At T4, the expression of all
the tested genes was significantly lower in supplemented cells
than in unsupplemented ones and comparable to the expres-
sion level observed in unsupplemented cells at the first stages
of differentiation.
The antiadipogenic effect of DHA, GEN, and SFN has
been already reported in previous earlier studies [16–19].
Our study is not simply a confirmation that the tested bioac-
tives act mainly through modification of the adipocyte life
cycle [8], but mainly a representation of the first study
comparing the effectiveness of DHA, GEN, and SFN in
the same experimental conditions. Although GEN and SFN
appeared effective at lower concentrations than DHA did, it
is worth noting that in vivo the latter is absorbed and
delivered to peripheral cells in its parent form. GEN and
SFN are extensively metabolized, and they are detectable
at very low concentrations in the bloodstream [37–39].
On the contrary, the DHA concentration used in this
study for cell supplementation is easily reachable in vivo
in the human plasma [40–42].
5. Conclusions
Our results represent an additional step in the evaluation
of the antiadipogenic effects of three natural bioactive
molecules, DHA, GEN, and SFN. Although in vitro all
tested bioactive compounds appeared to be putative con-
tributors to the prevention and treatment of obesity, their
in vivo metabolism suggests that mainly DHA could
potentially be used for the formulation of new functional
food products devoted to a new dietetic natural strategy
for overweight counteraction.
Further investigations are needed to verify whether the
antiadipogenic properties evidenced in vitro do translate into
in vivo efficacy in humans and to sort out the pathway(s)
responsible for the beneficial effects. Moreover, the
compounds here considered have been studied as discrete
molecules and not as part of a food, ignoring both the matrix
effect and the eventual synergistic or enhanced activities
between the selected compounds and other food components
or other bioactive molecules [43]. This issue also deserves
future attention.
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